Christopher Seet

Assistant Professor

David Geffen School of Medicine at UCLA

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Christopher Seet is an Assistant Professor at the David Geffen School of Medicine at UCLA, USA. His research focuses on cancer immunotherapy, including the discovery of therapeutic targets through alternative splicing and the development of engineered T cells for cancer treatment. He has contributed to studies on T cell differentiation, 3D-organoid cultures, and the role of immune cells in disease management.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (4)

Gay M. Crooks

UNITED STATES

View details

David Siegel

Chief, Myeloma Division

UNITED STATES

View details

John Lee

Associate Professor-in-Residence

University of California, Los Angeles

UNITED STATES

View details

Weixian Deng

David Geffen School of Medicine at UCLA

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christopher Seet

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing

Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing.

Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells.

Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation.

Generation of Artificial Thymic Organoids from Human and Murine Hematopoietic Stem and Progenitor Cells.

3D-organoid culture supports differentiation of human CAR<sup>+</sup> iPSCs into highly functional CAR T cells.

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.

Latency reversal plus natural killer cells diminish HIV reservoir in vivo

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.

Collaborators (4)

Gay M. Crooks

David Siegel

John Lee

Weixian Deng

Make your next move.